Quick Answer
Arbutus Biopharma Corp reported Operating Income Loss of -$38.16 million for the year ending 2025.
- Arbutus Biopharma Corp showed an increase of +50.0% in Operating Income Loss from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$2.99 million | Q2 2013: -$3.07 million | Q3 2013: -$3.65 million | Q4 2013: -$2.44 million | Q1 2014: -$5.96 million | Q2 2014: -$9.42 million | Q3 2014: -$6.84 million | Q4 2014: -$10.75 million | Q1 2015: -$18.01 million | Q2 2015: -$14.42 million | Q3 2015: -$58.14 million | Q4 2015: -$11.76 million | Q1 2016: -$19.98 million | Q2 2016: -$195.25 million | Q3 2016: -$18.98 million | Q4 2016: -$257.44 million | Q1 2017: -$18.30 million | Q2 2017: -$19.49 million | Q3 2017: -$12.90 million | Q4 2017: -$60.25 million | Q1 2018: -$18.41 million | Q2 2018: -$22.05 million | Q3 2018: -$32.43 million | Q4 2018: -$16.90 million | Q1 2019: -$19.20 million | Q2 2019: -$20.65 million | Q3 2019: -$91.03 million | Q4 2019: -$13.09 million | Q1 2020: -$13.15 million | Q2 2020: -$13.14 million | Q3 2020: -$15.22 million | Q1 2021: -$15.68 million | Q2 2021: -$18.64 million | Q3 2021: -$18.41 million | Q1 2022: -$10.97 million | Q2 2022: -$14.11 million | Q3 2022: -$17.81 million | Q1 2023: -$17.41 million | Q2 2023: -$18.39 million | Q3 2023: -$21.56 million | Q1 2024: -$19.36 million | Q2 2024: -$21.58 million | Q3 2024: -$21.44 million | Q1 2025: -$25.70 million | Q2 2025: $1.49 million | Q3 2025: -$8.66 million.
- Over the full 17 years of available data (2009 to 2025), Arbutus Biopharma Corp's Operating Income Loss has declined by 350.2%.
- Historical annual values: Fiscal year 2025: -$38.16 million | Fiscal year 2024: -$76.32 million | Fiscal year 2023: -$78.10 million | Fiscal year 2022: -$65.46 million | Fiscal year 2021: -$73.52 million | Fiscal year 2020: -$57.81 million | Fiscal year 2019: -$143.90 million | Fiscal year 2018: -$89.78 million | Fiscal year 2017: -$110.93 million | Fiscal year 2016: -$491.64 million | Fiscal year 2015: -$103.92 million | Fiscal year 2014: -$33.43 million | Fiscal year 2013: -$12.15 million | Fiscal year 2012: -$12.95 million | Fiscal year 2011: -$10.69 million | Fiscal year 2010: -$12.52 million | Fiscal year 2009: -$8.48 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: